Medically, and per ann, less than 15% inoperable pc sufferers become resectable after receiving soc e.g. chemo.
Per ann, 2/20 i.e. 10% inoperable pc sufferers who received chemo plus oncosil became resectable.
Lack of any statistical significance aside, could the regulators argue addition of oncosil worsens the efficacy of chemo?
Medically, I'm still not seeing a clinical / medical benefit that justifies addition of oncosil to chemo. The final resectable decision currently under review for additional 3/20 oncosil recipients will be important. Ann seems premature without this information. Perhaps not without intention given what's at stake.
OSL Price at posting:
14.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)